位置:首页 > 产品库 > ATB-343
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ATB-343
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ATB-343图片
CAS NO:1000700-26-4
规格:98%
分子量:566.1
包装与价格:
包装价格(元)
1mg询价
5mg询价
10mg询价
50mg询价

hybrid molecule of an H2S donor and the NSAID indomethacin
CAS:1000700-26-4
分子式:C28H20ClNO4S3
分子量:566.1
纯度:98%
存储:Store at -20°C

Background:

ATB-343, also named as indomethacin, is an H2S-releasing derivative of indomethacin [1].


Hydrogen sulfide (H2S) is a newly recognized signaling molecule with potent cytoprotective actions. Hydrogen sulfide has been involved in mediating many physiological processes, such as the maintenance of gastrointestinal mucosal defense and repair. Hydrogen sulfide also exerts many anti-inflammatory effects, including inhibition of leukocyte adherence to the vascular endothelium and leukocyte migration to sites of inflammation [2].


In vitro: Indomethacin enhanced the NK cell activity in vitro by blocking the prostaglandin production of monocytes [3].


In vivo: In rats, oral administration of ATB-343 significantly inhibited gastric prostaglandin synthesis and systemic COX-1 activity [1]. Indomethacin was a potent inhibitor of prostaglandin synthesis. Indomethacin suppressed in vivo thyroid hormone secretion and cholera toxin-induced intestinal fluid accumulation. Indomethacin in submicromolar concentrations inhibited cyclic AMP-dependent protein kinase and endogenous protein phosphorylation [4].


Clinical trials: Indomethacin has entered clinical trial in Alzheimer's disease [5].


参考文献:
[1] Wallace J L.  Hydrogen sulfide-releasing anti-inflammatory drugs[J]. Trends in Pharmacological Sciences, 2007, 28(10): 501-505.
[2] Wallace J L.  Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract[J]. Antioxidants & redox signaling, 2010, 12(9): 1125-1133.
[3] Pedersen B K, Oxholm P, Klarlund K.  Characterization of the in vivo and in vitro effects of indomethacin on human natural killer cell activity[J]. Allergy, 1986, 41(7): 532-536.
[4] Kantor H S, Hampton M.  Indomethacin in submicromolar concentrations inhibits cyclic AMP-dependent protein kinase[J]. 1978.
[5] Rogers J, Kirby L C, Hempelman S R, et al.  Clinical trial of indomethacin in Alzheimer's disease[J]. Neurology, 1993, 43(8): 1609-1609.


 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024